| abstract |
The present invention is directed to a spiro compound which is an inhibitor of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), for use in the treatment of diseases or conditions associated with peripheral serotonin, including, for example, the gastrointestinal tract , cardiovascular, pulmonary, inflammatory, metabolic and low bone quality diseases as well as serotonin syndrome and cancer. |